Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.54 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5778010 | 1.00 | GPR119 (0.54) | GPR119JAK3MEN1MAPTTSHR | |
| SCHEMBL5779732 | 0.82 | JAK3 (0.64) | JAK3MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL5779730 | 0.82 | JAK3 (0.64) | JAK3MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL5775757 | 0.79 | JAK3 (0.47) | JAK3MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL5775753 | 0.79 | JAK3 (0.47) | JAK3MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL5778056 | 0.77 | HDAC1 (0.43) | GPR119MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL5777455 | 0.77 | JAK3 (0.51) | GPR119JAK3CA2CA7CA9 | |
| SCHEMBL5777456 | 0.77 | JAK3 (0.51) | GPR119JAK3CA2CA7CA9 | |
| SCHEMBL5779808 | 0.76 | GPR119 (0.46) | GPR119MAPT | |
| SCHEMBL5779815 | 0.76 | GPR119 (0.46) | GPR119MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | GPR119 2675/4885JAK3 4560/4885MEN1 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.